She looks to you to manage both risks

As postmenopausal woman with osteoporosis, she may be at risk of osteoporotic fracture and invasive breast cancer.

Only Evista is indicated to treat osteoporosis and reduce the risk of invasive breast cancer in post menopausal women with osteoporosis.

Cut 2 risks.
Invasive breast cancer
Osteoporotic fractures

More than 64 million prescriptions filled since FDA approval in 1997.

Brand name: Evista
Generic name/category: Raloxifene, Benzothiophenes, Piperidines, Selective estrogen receptor modulators
Company: Eli Lilly
Country/Market: USA, North America
Indication(s)/use: osteoporosis and reduce the risk of invasive breast cancer in post menopausal women with osteoporosis
Target: Healthcare Professionals (HCP)
Tagline: Protect her bones. Protect her breasts.
Publication: Contemporary ob/gyn June 2009

To see all of this brand’s ads on AdPharm, click here